RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Seth Y. Ablordeppey to Haloperidol

This is a "connection" page, showing publications Seth Y. Ablordeppey has written about Haloperidol.
Connection Strength

4.494
  1. Asong G, Zhu XY, Bricker B, Andey T, Amissah F, Lamango N, Ablordeppey SY. New analogs of SYA013 as sigma-2 ligands with anticancer activity. Bioorg Med Chem. 2019 06 15; 27(12):2629-2636.
    View in: PubMed
    Score: 0.668
  2. Al-Ghanim L, Zhu XY, Asong G, Ablordeppey SY. SYA 013 analogs as moderately selective sigma-2 (s2) ligands: Structure-affinity relationship studies. Bioorg Med Chem. 2019 06 15; 27(12):2421-2426.
    View in: PubMed
    Score: 0.659
  3. Sampson D, Bricker B, Zhu XY, Peprah K, Lamango NS, Setola V, Roth BL, Ablordeppey SY. Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 01; 24(17):4294-7.
    View in: PubMed
    Score: 0.481
  4. Bricker B, Jackson T, Boateng B, Zhu XY, Ablordeppey SY. Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. Pharmacol Biochem Behav. 2012 Aug; 102(2):294-301.
    View in: PubMed
    Score: 0.414
  5. Peprah K, Zhu XY, Eyunni SV, Etukala JR, Setola V, Roth BL, Ablordeppey SY. Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol. Bioorg Med Chem. 2012 Mar 01; 20(5):1671-8.
    View in: PubMed
    Score: 0.405
  6. Peprah K, Zhu XY, Eyunni SV, Setola V, Roth BL, Ablordeppey SY. Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents. Bioorg Med Chem. 2012 Feb 01; 20(3):1291-7.
    View in: PubMed
    Score: 0.403
  7. Ablordeppey SY, Lyles-Eggleston M, Bricker B, Zhang W, Zhu X, Goodman C, Roth BL. Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol. Bioorg Med Chem Lett. 2006 Jun 15; 16(12):3219-23.
    View in: PubMed
    Score: 0.272
  8. Sikazwe DM, Li S, Mardenborough L, Cody V, Roth BL, Ablordeppey SY. Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors. Bioorg Med Chem Lett. 2004 Dec 06; 14(23):5739-42.
    View in: PubMed
    Score: 0.247
  9. Lyles-Eggleston M, Altundas R, Xia J, Sikazwe DM, Fan P, Yang Q, Li S, Zhang W, Zhu X, Schmidt AW, Vanase-Frawley M, Shrihkande A, Villalobos A, Borne RF, Ablordeppey SY. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species. J Med Chem. 2004 Jan 29; 47(3):497-508.
    View in: PubMed
    Score: 0.233
  10. Sikazwe DM, Li S, Lyles-Eggleston M, Ablordeppey SY. The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 03; 13(21):3779-82.
    View in: PubMed
    Score: 0.229
  11. Bricker B, Sampson D, Ablordeppey SY. Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument. Pharmacol Biochem Behav. 2014 May; 120:109-16.
    View in: PubMed
    Score: 0.117
  12. Ablordeppey SY, Borne RF. Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats. Pharmacol Biochem Behav. 1993 Nov; 46(3):739-44.
    View in: PubMed
    Score: 0.115
  13. Billups J, Jones C, Jackson TL, Ablordeppey SY, Spencer SD. Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. Biomed Chromatogr. 2010 Jul; 24(7):699-705.
    View in: PubMed
    Score: 0.091
  14. Sikazwe DM, Nkansah NT, Altundas R, Zhu XY, Roth BL, Setola V, Ablordeppey SY. Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups. Bioorg Med Chem. 2009 Feb 15; 17(4):1716-23.
    View in: PubMed
    Score: 0.082
  15. Ablordeppey SY, Altundas R, Bricker B, Zhu XY, Kumar EV, Jackson T, Khan A, Roth BL. Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorg Med Chem. 2008 Aug 01; 16(15):7291-301.
    View in: PubMed
    Score: 0.079
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support